Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 89 of the 89 references it cites were found in a registry or an index.

Molecular Therapies for Tuberous Sclerosis and Neurofibromatosis

Franz, David Neal, Weiss, Brian D. · 2012 · Current Neurology and Neuroscience Reports

Abstract

Neurofibromatosis type 1 (NF1) and tuberous sclerosis complex (TSC) are autosomal-dominant genetic disorders that result from dysregulation of the PI3K/AKT/mammalian target of rapamycin (mTOR) pathway. NF1 is caused by mutations in the NF1 gene on chromosome 17q11.2. Its protein product, neurofibromin, functions as a tumor suppressor and ultimately produces constitutive upregulation of mTOR. TSC is caused by mutations in either the TSC1 (chromosome 9q34) or TSC2 (chromosome 16p.13.3) genes. Their protein products, hamartin and tuberin, respectively, form a dimer that acts via the GAP protein Rheb (Ras homolog enhanced in brain) to directly inhibit mTOR, again resulting in upregulation. Specific inhibitors of mTOR are in clinical use, including sirolimus, everolimus, temsirolimus, and deforolimus. Everolimus has been shown to reduce the volume and appearance of subependymal giant cell astrocytomas (SEGA), facial angiofibromas, and renal angiomyolipomas associated with TSC, with a recent FDA approval for SEGA not suitable for surgical resection. This article reviews the use of mTOR inhibitors in these diseases, which have the potential to be a disease-modifying therapy in these and other conditions.

Overview

Integrity signals

Registry

Crossref · 10.1007/s11910-012-0269-4

Cites

89 of 89 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 89 references

Research works printed but not linked: 3

  1. Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Waldron W, et al. SEER Cancer Statistics Review, 1975–2008. National Cancer Institute, Bethesda, MD; 2010.
  2. US Department of Health and Human Services, National Institutes of Health. Neurofibromatosis. NIH Consens Statement Online 1987 Jul 13–15;6(12):1–19.
  3. Ricardi VM, Eichner JE. Neurofibromitosis: phenotype, natural history and pathogenesis. Baltimore: Johns Hopkins University Press; 1986.

Cited by

See all 62

Metadata

Authors
Franz, D. N., & Weiss, B. D.
Affiliations
Cincinnati Children's Hospital Medical Center (US)
Corresponding author
Franz, David Neal
Venue
Current Neurology and Neuroscience Reports
Published
2012-04-29
Volume
12
Issue
3
Pages
294-301
ISSN
  • 1528-4042 (ISSN-L)
  • 1534-6293
OpenAlex
W2160872337
Cited by
58
References
89
Citations by year
2026: 1 · 2024: 5 · 2023: 1 · 2022: 2 · 2021: 6 · 2020: 2 · 2019: 2 · 2018: 3 · 2017: 4 · 2016: 2 · 2015: 8 · 2014: 14 · 2013: 6 · 2012: 2
FWCI
1.03
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)
Locations
  • Current Neurology and Neuroscience Reports (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Genetics (clinical) › Tuberous Sclerosis Complex Research
  • Health Sciences › Medicine › Clinical Neurology › Neurofibromatosis and Schwannoma Cases
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
Keywords
tuberous sclerosis complex, neurofibromatosis type 1, mTOR inhibitors, PI3K/AKT/mTOR pathway, neurofibromin, hamartin, tuberin, Rheb, rapamycin, everolimus, temsirolimus, subependymal giant cell astrocytoma, facial angiofibroma, renal angiomyolipoma, disease-modifying therapy
MeSH terms
Humans, Neurofibromatosis 1, Tuberous Sclerosis, Signal Transduction, TOR Serine-Threonine Kinases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Molecular Therapies for Tuberous Sclerosis and Neurofibromatosis. https://app.cochat.ai/papers/10.1007/s11910-012-0269-4
The paper
Franz, D. N., & Weiss, B. D. (2012). Molecular Therapies for Tuberous Sclerosis and Neurofibromatosis. Current Neurology and Neuroscience Reports. https://doi.org/10.1007/s11910-012-0269-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.